For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Our Abpromise guarantee covers the use of ab53824 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The ED50 for stimulation of 3H-thymidine incorporation and cell proliferation by human umbilical vein endothelial cells for VEGF has been determined to be in the range of 10 ng/ml.
Specific activity: 2.5 x 105 units/mg.
A vascular endothelial growth factor (VEGF) mRNA species containing exons 1–6 and 8 of the VEGF gene was found to be expressed as a major VEGF mRNA form in several cell lines derived from carcinomas of the female reproductive system. This mRNA is predicted to encode a VEGF form of 145 amino acids (VEGF145). VEGF145 produced in insect cells is a homodimeric, 20,5 kDa protein belonging to the VEGFA family. Recombinant VEGF145 (ab53824) induced the proliferation of vascular endothelial cells and promoted angiogenesis in vivo. VEGF145 binds to the KDR/flk-1 receptor and to heparin. VEGF145 does not bind to two additional endothelial cell surface receptors that are recognized by VEGF165. VEGF145 binds efficiently to ECM becoming active. Binding of VEGF145 to ECM was not affected by heparinase digestion. Therefore, it has a unique combination of biological properties distinct from those of previously characterized VEGF species.
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
ab53824 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"